Li Yumeng, Qiu Hua, Zhao Zhenzhen, Qi Fanghua, Cai Pingping
The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, China.
Gynecology, Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan, China.
Front Immunol. 2025 Jul 2;16:1636483. doi: 10.3389/fimmu.2025.1636483. eCollection 2025.
Globally, endometrial cancer continues to impact a significant number of women. Immunotherapy provides those suffering from advanced or relapsed disease hope, but an important barrier is still the absence of trustworthy predictive biomarkers. To tackle this challenge, single-cell sequencing and spatial transcriptomics (ST) are increasingly applied. In cervical cancers of the no specific molecular profile (NSMP) subtype accompanied by p53 mutations. In many cases, the tumor microenvironment (TME) in endometrial cancer exhibits strong immunosuppression or poor immune cell infiltration, often leading to worse clinical outcomes. Single-cell sequencing reveals cellular heterogeneity and helps identify potential therapeutic targets and predict treatment responses. Conversely, ST assists in determining biomarkers that influence the effectiveness of immunotherapy by capturing the spatial organization of tumors. When combined, these technologies allow for integrated multi-omics analysis that aids in the development of immunotherapies, prognostication, and diagnosis. But there are still moral and legal issues. Clinicians may be able to improve outcomes for patients who don't respond well to current immunotherapies by utilizing these combined approaches.
在全球范围内，子宫内膜癌持续影响着大量女性。免疫疗法为晚期或复发性疾病患者带来了希望，但一个重要障碍仍然是缺乏可靠的预测性生物标志物。为应对这一挑战，单细胞测序和空间转录组学（ST）的应用越来越广泛。在伴有p53突变的无特定分子谱（NSMP）亚型宫颈癌中。在许多情况下，子宫内膜癌的肿瘤微环境（TME）表现出强烈的免疫抑制或免疫细胞浸润不良，常常导致更差的临床结果。单细胞测序揭示了细胞异质性，有助于识别潜在的治疗靶点并预测治疗反应。相反，ST通过捕捉肿瘤的空间组织，协助确定影响免疫疗法疗效的生物标志物。将这些技术结合使用，可以进行综合多组学分析，有助于免疫疗法的开发、预后评估和诊断。但仍然存在道德和法律问题。临床医生或许可以通过利用这些联合方法，改善对当前免疫疗法反应不佳的患者的治疗效果。
